Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
C4 Therapeutics ( (CCCC) ) just unveiled an update.
On April 8, 2026, C4 Therapeutics entered a new research collaboration and license agreement with Roche to discover, develop and commercialize degrader-antibody conjugates for two undisclosed oncology targets, with an option for a third. Roche will lead development, regulatory work, manufacturing and commercialization, while C4T designs degrader payloads using its TORPEDO platform and retains eligibility for tiered royalties on future net sales.
Under the deal, C4 Therapeutics will receive a $20 million upfront payment, near-term discovery milestones and could earn more than $1 billion in development, regulatory and commercial milestone payments over time. Announced publicly on April 9, 2026, the expanded partnership deepens a decade-long relationship with Roche, reinforces C4T’s position in the emerging DAC modality and provides significant non-dilutive funding potential that could support its broader oncology pipeline.
The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
Spark’s Take on CCCC Stock
According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, cash burn, and 2025 revenue dropping to $0), only partially offset by a stronger balance sheet. Technicals are supportive with an uptrend, but overbought signals temper the near-term setup. Valuation is constrained by unprofitability, while the recent corporate strategy update and stated runway to 2028 provide a meaningful, but secondary, positive catalyst.
To see Spark’s full report on CCCC stock, click here.
More about C4 Therapeutics
C4 Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop small-molecule medicines for difficult-to-treat diseases, primarily in oncology. Leveraging its proprietary TORPEDO platform, the company designs heterobivalent and molecular glue degraders, as well as degrader-antibody conjugate payloads, aiming to overcome drug resistance and address undruggable targets.
Average Trading Volume: 2,140,973
Technical Sentiment Signal: Hold
Current Market Cap: $283M
See more insights into CCCC stock on TipRanks’ Stock Analysis page.